The. prevalence of the risk factor is an additional important determinant of the potential benefit of screening for the community. This ranged from the prevention -of 25 deaths from coronary heart disease over five years in women aged 25-34 to the prevention of 11 568 deaths in men aged 55-64. Reducing the mean cholesterol concentration of the population by 0 5 mmol/l by reducing,the prevalence of high concentrations could reduce the mortality from coronary heart disease by 22%-about twice the reduction obtained with the strategy of screening and treatment.
These results are illustrative not definitive. Rates of coronary heart disease and prevalences of high cholesterol concentrations differ in different groups of people and blanket recommendations based on relative risks alone are inadequate. We did not consider cost effectiveness or other potential benefits or risks of screening and treatment. We believe, however, that this approach to examining data on high cholesterol concentrations may be ofvalue in highlighting not only points of qualitative uncertainty, such as local prevalences of high cholesterol concentrations and the mortality associated with a given concentration but also, more importantly, points of qualitative uncertainty, such as the long term benefits and risks of treatment that lowers cholesterol concentration and what these are in groups not studied in trials-that is, women and certain age and ethnic groups. The principal constraints affecting the programme of immunisation seem to be the cost of the vaccine and the resources of occupational health departments. Costs may be reduced by giving a lower dose of vaccine intradermally. Five districts used the intradermal route (one for all three doses of vaccine and four for the second and third doses); the other departments used standard doses intramuscularly. The intradermal route is effective34 but is the subject of debate,5 and the product licence for hepatitis B vaccine is for only the intramuscular route. An alternative way in which districts may save money is by asking staff to get their general practitioners to prescribe the vaccine, so that costs are transferred to family practitioner committees' budgets. This, however, introduces an unnecessary hurdle for staff, which is likely to decrease take up. Family practitioner committees' budgets financed (or were planned to finance) 80% or more of the immunisations in five districts and a mean of 18% in a further-eight districts. This is a pragmatic solution for districts striving to keep within budgets but is a false economy for the NHS, which loses discounts of about 25% that are available to districts buying in bulk. These problems are unlikely to be resolved unless district health authorities and family practitioner committees are merged and given a common budget.
The financial constraints on the districts are unlikely to absolve them from their legal responsibilities to protect their workforce against hazards at work under the Health and Safety at Work Act (1974) and the Control of Substances Hazardous to Health Regulations, which are soon to be introduced.
